(RDHL) Mkap $61 M /Ein MUSS für jeden Biotech Investor (Seite 369)

[Jagubert]

Mal was zum an Kopf fassen von der Watchlist der DIBA:

USA (Nasdaq):
BID 0,01 ASK 199.999,99
Spread: 1.999.999.800,00% 18.07.14 02:10

[praslin0808]

Könnte ein kleiner Startschuss in die richtige Richtung sein

[praslin0808]

http://money.cnn.com/news/newsfeeds/articles/globenewswire/1…

[Sugar2000]

REDHILL BIOPHARMA LTD RDHL.O: ROTH CAPITAL RAISES TARGET PRICE TO $24 FROM $20; RATING BUY RDHL.O RDHL.TA - RTRS

[Biohero]

Antwort auf Beitrag Nr.: 47.232.630 von sauerback am 30.06.14 13:10:15

Ein guter Deal für RDHL ,ein intressanter Wirkstoff und das für nur $1 M vorabzahlung . Produkt Pipeline wird immer größer und besser .

[sauerback]

DGAP-Adhoc: WILEX AG: WILEX und RedHill Biopharma schließen exklusive Lizenzvereinbarung für MESUPRON(R) ab (deutsch)

http://www.finanztreff.de/news/dgap-adhoc-wilex-ag-wilex-und…

[giesarazu]

RedHill Biopharma Announces Positive Preliminary Pre-Clinical Data With RHB-104 for the Treatment of Type 1 Diabetes

http://ir.redhillbio.com/secfiling.cfm?filingid=1171843-14-3…

noch keinerlei Kurs-Reaktion... werde hier Montag einsteigen

[Biohero]

Hier könnte es demnächst richtig spannend werden denn im 3Q werden die Phase 3 Daten für den potenziellen Blockbuster RHB-105 (Helicobacter-pylori-Infektion) veröffentlicht . Die Chancen für gute Daten stehen nicht schlecht weil eine Phase 2 Studie mit 130 patienten positiv verlaufen ist die Phase 3 Studie hat nur 90 Patienten .Sind die Daten gut dann dürfte es wegen dem sehr niedrigen Float von nur 4 Million schnell richtung $50 gehen die ich auch im ersten Posting angegeben habe .

Redhill hat aber noch viel mehr zubieten als nur den Kandidaten siehe Produkt Pipeline unten .Mit einer Marktkap von $160 M (davon $38 M in Cash ) ist RDHL im vergleich zu den meisten US Biotechs ein Schnäppchen .


Neue Präsentation
http://files.shareholder.com/downloads/AMDA-1C0OBF/324198356…

2014: Selected Potential Milestones

RHB-104 Planned commencement of a European Phase III study
in Crohn’s disease

RHB-105 Phase III H. pylori eradication data expected Q3/2014

RHB-103 New PDUFA date to be assigned by FDA following CRL* received
Feb.2014

RHB-103 Planned filing of European marketing application in Q3/2014

RHB-102
-Planned filing of European marketing application in Q3/2014 for CINV
and RINV indications

-Phase III study for undisclosed indication planned to commence Q3/2014

[Jon_Schnee]

RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement

TEL-AVIV, Israel, Jan. 14, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today announced that it has entered into a definitive agreement with a select group of investors (the "Investors") for the sale of RedHill's ordinary shares and warrants in a private placement transaction (the "Private Placement") for a total amount of approximately $11.7 million.

The Investors in the Private Placement include Israeli institutional investors Migdal Insurance Company, Yelin Lapidot, and Excellence Nessuah, as well as Sphera Global Healthcare Master Fund and additional private Israeli investors.

Proceeds from the financing will be used for general working capital and for research and development related purposes, including the clinical development of RHB-104 for Crohn's disease and RHB-105 for H. pylori infection, both currently undergoing Phase III studies in the U.S., and for potential acquisitions.

The Private Placement is expected to close by the end of January 2014, subject to the satisfaction of certain customary closing conditions. Upon the closing of the Private Placement, in exchange for gross proceeds of approximately $11.7 million, RedHill will issue to the Investors a total of 10,458,740 ordinary shares at a purchase price of 3.9 NIS per ordinary share, and warrants to purchase a total of 4,183,496 ordinary shares, which will have a three-year term and be exercisable at a price per share of 4.9 NIS, linked to changes in the NIS-US dollar exchange rate. For a detailed description of the terms of the Private Placement, please see the Company's Report on Form 6-K furnished to the Securities and Exchange Commission (the "SEC") on January 14, 2014.

The ordinary shares and warrants offered in the Private Placement and the ordinary shares issuable upon the exercise of the warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States unless such sale is made pursuant to an effective registration statement filed with the SEC or pursuant to an applicable exemption from SEC registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About RedHill Biopharma Ltd.:

RedHill Biopharma Ltd. (RDHL) (RDHL) is an emerging Israeli biopharmaceutical company focused

[dottore]

Redhill und IntelGenx versuchen eine Verpartnerung des Rizatriptans ....

http://www.intelgenx.com/pipeline/

http://www.wallstreet-online.de/aktien/intelgenx-tech-aktie